Fig. 7: Vemurafenib combined with E3330 treatment offered a relatively promising therapeutic strategy in vivo. | Cell Death & Disease

Fig. 7: Vemurafenib combined with E3330 treatment offered a relatively promising therapeutic strategy in vivo.

From: Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib

Fig. 7

A Representative images of dissected mouse subcutaneous tumors after HMC, vemurafenib, E3330, or combination (vemurafenib + E3330) treatment for 21 days. B The weights of mouse subcutaneous tumors after different treatments for 21 days. C Change in tumor volume after HMC, vemurafenib, E3330, or combination (vemurafenib + E3330) treatment for 21 days. D The body weight changes of mice measured every 3 days after different treatments. E Representative H&E staining of tumors, livers, and kidneys after different treatments. F Representative immunohistochemical staining for p-ERK, Ki-67, cl-caspase3, and γH2AX after different treatments. G Representative images of mouse metastatic tumors after HMC, vemurafenib, E3330, or combination (vemurafenib + E3330) treatment for 21 days. H Representative H&E staining of metastatic tumors in the lungs and livers. I Representative immunohistochemical staining for Ki-67, Vimentin, LC3B, and p62 after different treatments. **P < 0.01, ***P < 0.001.

Back to article page